Mesothelioma Surgery Options 2026: EPP vs P/D and Emerging Techniques

Surgery remains the cornerstone of treatment for mesothelioma patients who are healthy enough to undergo major operations. The two primary surgical approaches for pleural mesothelioma—extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D)—offer different trade-offs between tumor removal and lung preservation [1]. At experienced centers, surgical patients achieve median survival times of 18-24 months, with some patients surviving 5 years or longer [2]. For patients with peritoneal mesothelioma, CRS-HIPEC surgery achieves 5-year survival rates of approximately 47% in multi-institutional studies, with higher rates reported at specialized centers [3].

10 Key Facts About Mesothelioma Surgery in 2026

• 30-Day Mortality (P/D): Approximately 2% in meta-analysis of published studies [1]
• 30-Day Mortality (EPP): Approximately 5% in meta-analysis of published studies [1]
• P/D Median Survival: Approximately 18-24 months with multimodal treatment for pleural mesothelioma [1]
• CRS-HIPEC 5-Year Survival: 47% for peritoneal mesothelioma in multi-institutional data [3]
• Surgical Candidacy: An estimated 20-30% of pleural mesothelioma patients may qualify for surgery [2]
• Hospital Stay: Generally 7-14 days for major procedures, varying by procedure type
• Recovery Time: Typically 2-4 months to full activity, depending on procedure
• Center Volume Matters: High-volume centers show significantly lower 90-day mortality [4]
• Perioperative Immunotherapy: 80% surgical success rate in trials [5]
• Best Outcomes: Epithelioid type, early-stage, multimodal treatment

What Are the Main Surgical Options for Pleural Mesothelioma?

Two major surgical procedures treat pleural mesothelioma: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). Understanding the differences helps patients make informed decisions with their surgical team.

Extrapleural Pneumonectomy (EPP)

EPP is the more radical procedure, removing multiple structures from the affected side of the chest:

• Entire lung: Complete removal of the diseased lung
• Parietal pleura: Lining of the chest wall
• Visceral pleura: Lining covering the lung
• Pericardium: Membrane surrounding the heart (partially)
• Diaphragm: The breathing muscle (ipsilateral portion)

The goal of EPP is macroscopic complete resection—removing all visible tumor [1]. The diaphragm and pericardium are reconstructed with synthetic patches.

EPP may be preferred when:

• Tumor extensively involves the lung tissue
• Fissures between lung lobes are invaded
• Complete removal requires lung sacrifice
• Patient has adequate pulmonary reserve in the remaining lung

Pleurectomy/Decortication (P/D)

P/D removes the diseased pleural lining while preserving the lung itself:

• Parietal pleura: Complete removal of chest wall lining
• Visceral pleura: Stripping of the tumor from the lung surface
• Visible tumor nodules: Removal from chest wall, diaphragm, pericardium
• Lung preservation: The underlying lung remains intact

Extended P/D may include diaphragm and/or pericardium resection when involved by tumor, similar to EPP but without lung removal.

"The shift toward lung-sparing surgery has been one of the most significant changes I've seen in mesothelioma care. Patients recover faster, maintain better breathing capacity, and—importantly—the survival numbers are comparable. But the right surgery depends on the individual case, which is why choosing an experienced team matters so much."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Do EPP and P/D Compare in 2026?

The debate between EPP and P/D has evolved significantly, with most major centers now favoring lung-sparing surgery [1].

Survival Outcomes

Factor	EPP	P/D
Median Survival	15-20 months	18-24 months
30-Day Mortality	~5%	~2%
Major Complications	~46%	~24%
Hospital Stay	10-14 days	7-10 days
Recovery Time	3-4 months	2-3 months

Quality of Life

P/D generally offers better quality of life outcomes:

• Preserved lung function: Patients retain more breathing capacity
• Faster recovery: Return to normal activities sooner
• Lower complication rates: Fewer postoperative problems
• Better exercise tolerance: Ability to maintain physical activity

When EPP May Still Be Preferred

Despite the trend toward P/D, EPP remains appropriate in specific situations:

• Extensive involvement of the lung parenchyma
• Tumor invasion into the fissures
• When complete resection is not possible with P/D
• Younger, fit patients with excellent contralateral lung function

Who Is a Candidate for Mesothelioma Surgery?

Not all mesothelioma patients are surgical candidates. An estimated 20-30% of pleural mesothelioma patients may qualify for potentially curative surgery [2].

Favorable Factors for Surgery

• Epithelioid histology: Best-responding cell type to surgery
• Early stage (I-III): Disease confined to one side of the chest
• Good performance status: ECOG 0-1 (active, able to care for self)
• Adequate pulmonary function: FEV1 >1.5L or >40% predicted
• Cardiac health: Ability to tolerate major surgery
• No distant metastases: Cancer hasn't spread to other organs

Factors That May Preclude Surgery

• Sarcomatoid histology: Aggressive type with poor surgical outcomes
• Advanced stage (IV): Distant spread or contralateral disease
• Poor performance status: Unable to tolerate major surgery
• Significant comorbidities: Heart disease, COPD, kidney failure
• Inadequate pulmonary reserve: Wouldn't tolerate lung removal (for EPP)

The Importance of Staging

Accurate staging is essential before surgery. Staging workup typically includes:

• CT scan: Detailed chest imaging
• PET scan: Identifies distant spread
• MRI: Evaluates chest wall and diaphragm involvement
• Mediastinoscopy: Sampling of lymph nodes
• Pulmonary function tests: Assesses breathing capacity
• Cardiac evaluation: Ensures heart can tolerate surgery

Learn more about understanding your mesothelioma diagnosis and staging.

What Is CRS-HIPEC Surgery for Peritoneal Mesothelioma?

Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) has transformed outcomes for peritoneal mesothelioma [3].

The CRS-HIPEC Procedure

CRS-HIPEC is a two-part procedure performed during a single operation:

1. Cytoreductive surgery (CRS): Removal of all visible tumor from the abdominal cavity, including peritoneum, omentum, and involved organs if necessary
2. HIPEC: Heated chemotherapy (typically cisplatin or mitomycin C at 41-42°C) is circulated through the abdomen for 60-90 minutes

The heat enhances chemotherapy penetration and directly kills remaining microscopic cancer cells.

CRS-HIPEC Outcomes

At experienced centers, CRS-HIPEC achieves remarkable results [3]:

• 5-year survival: 47% in multi-institutional data (substantially higher than systemic chemotherapy alone)
• Median survival: 53 months in the largest multi-institutional registry
• Complete cytoreduction: Critical factor—correlates with best outcomes
• Operative mortality: 1-4% at experienced centers

"CRS-HIPEC is one of the great success stories in mesothelioma treatment. I've worked with peritoneal patients who are now 7, 8, even 10 years out from their surgery. But the key word is 'experienced center'—these are complex 8-12 hour operations that require specialized teams."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Peritoneal Mesothelioma Surgical Candidacy

Factors favoring CRS-HIPEC success:

• Epithelioid cell type
• Limited peritoneal cancer index (PCI) score
• No extra-abdominal spread
• Good nutritional status
• Ability to achieve complete cytoreduction (CC-0 or CC-1)

What Emerging Surgical Techniques Are Available in 2026?

Mesothelioma surgery continues to evolve with new techniques and combination approaches.

Perioperative Immunotherapy

Combining surgery with immunotherapy—given before and/or after the operation—is showing promising results [5]:

• Neoadjuvant immunotherapy: Checkpoint inhibitors before surgery
• 80% surgical completion rate: In perioperative trials
• 28.6-month median survival: Johns Hopkins trial results
• Improved pathologic response: More tumor cell death at surgery

Photodynamic Therapy (PDT)

PDT uses light-activated drugs to kill remaining cancer cells after surgical resection:

• Photosensitizing drug administered before surgery
• Special light applied to surgical cavity
• Activates drug to destroy residual tumor cells
• Being studied in combination with P/D

Tumor Treating Fields (TTFields)

TTFields uses electrical fields to disrupt cancer cell division and is now FDA-approved for use with chemotherapy. Research is evaluating its role in post-surgical treatment.

Intraoperative Chemotherapy Techniques

Beyond HIPEC for peritoneal disease, researchers are studying:

• Intrapleural chemotherapy: Direct delivery during thoracic surgery
• Pressurized aerosol chemotherapy (PIPAC): Nebulized drug delivery
• Hyperthermic intrathoracic chemotherapy (HITHOC): Heated chemo for pleural disease

Why Does Surgical Center Experience Matter?

Mesothelioma surgery outcomes vary dramatically based on where the operation is performed [4].

High-Volume vs. Low-Volume Centers

Factor	High-Volume Center	Low-Volume Center
90-Day Mortality	10.0%	14.6%
30-Day Readmission	4.6%	6.1%
Complete Resection Rate	Higher	Lower
Median Survival	18 months	15 months

What Makes a High-Volume Center?

• Case volume: Among the top decile of mesothelioma surgical programs by volume [4]
• Dedicated mesothelioma team: Specialized surgeons, oncologists, pathologists
• Multidisciplinary approach: Regular tumor board discussions
• Clinical trial access: Latest treatment options
• Support services: Palliative care, nutrition, rehabilitation

Leading Mesothelioma Surgical Centers

Centers known for mesothelioma surgical excellence include:

• Brigham and Women's Hospital — Boston, MA
• MD Anderson Cancer Center — Houston, TX
• Memorial Sloan Kettering — New York, NY
• Mayo Clinic — Rochester, MN
• Moffitt Cancer Center — Tampa, FL
• University of Pennsylvania — Philadelphia, PA

"I've been coordinating care for mesothelioma patients for 18 years, and I always emphasize: travel if you need to. A few hundred miles can mean the difference between a center that does 2 mesothelioma surgeries a year and one that does 50. That experience translates directly into better outcomes."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Should You Expect During Recovery?

Understanding the recovery process helps patients and families prepare.

Hospital Stay

• P/D: 7-10 days typical hospital stay
• EPP: 10-14 days typical hospital stay
• CRS-HIPEC: 10-14 days typical hospital stay
• ICU time: 1-3 days for major procedures

Early Recovery (Weeks 1-4)

• Chest tubes for drainage (removed within first week typically)
• Pain management with oral medications
• Walking and light activity encouraged
• Breathing exercises to prevent pneumonia
• Gradual increase in diet

Later Recovery (Months 1-3)

• Gradual return to normal activities
• Pulmonary rehabilitation for EPP patients
• Follow-up imaging to assess results
• Discussion of adjuvant treatment (chemotherapy, radiation)
• Quality of life typically returns to baseline by 6 months

Frequently Asked Questions

What is the difference between EPP and P/D surgery for mesothelioma?

Extrapleural pneumonectomy (EPP) removes the entire lung along with the pleura, diaphragm, and pericardium. Pleurectomy/decortication (P/D) removes the diseased pleural lining while preserving the lung. P/D has become preferred at most centers due to lower 30-day mortality rates (approximately 2% vs 5% in meta-analyses [1]) and faster recovery while achieving similar survival outcomes.

What is the survival rate for mesothelioma surgery?

Survival rates vary by procedure and patient factors. For pleural mesothelioma, P/D surgery combined with chemotherapy achieves median survival of approximately 18-24 months based on published meta-analyses. Peritoneal mesothelioma patients undergoing CRS-HIPEC can achieve 5-year survival rates of approximately 47% based on multi-institutional registry data [3].

Who is a candidate for mesothelioma surgery?

Surgical candidates typically have epithelioid cell type, early-stage disease (Stage I-III), good overall health (ECOG 0-1), adequate heart and lung function, and no distant metastases. Age alone doesn't disqualify patients—overall fitness matters more than chronological age.

How long is recovery from mesothelioma surgery?

Hospital stays generally range from 7-14 days for major mesothelioma surgery, depending on the procedure. Full recovery typically takes 2-3 months for P/D and 3-4 months for EPP. Many patients begin adjuvant chemotherapy 4-6 weeks after surgery. Quality of life typically returns to baseline within 6 months.

What is CRS-HIPEC surgery for peritoneal mesothelioma?

Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) is the gold standard for peritoneal mesothelioma. Surgeons remove all visible tumor, then circulate heated chemotherapy through the abdomen to kill remaining cancer cells. Multi-institutional registry data reports 5-year survival rates of approximately 47% [3].

Does mesothelioma surgery cure the cancer?

Surgery alone rarely cures mesothelioma, but it can significantly extend survival and improve quality of life. Most patients receive multimodal treatment combining surgery with chemotherapy and/or immunotherapy. Some patients achieve long-term survival of 5+ years with aggressive surgical treatment.

Next Steps: Evaluating Your Surgical Options

If you've been diagnosed with mesothelioma, understanding your surgical options is an essential part of treatment planning. The best approach depends on your specific diagnosis, overall health, and treatment goals.

Our patient advocacy team can help connect you with experienced mesothelioma surgical centers and specialists who perform these procedures regularly. We believe every patient deserves access to the most advanced surgical care available.

Related Resources

• Top 6 Mesothelioma Treatment Centers 2026 — Leading surgical programs
• Clinical Trials 2026 — Emerging treatment options
• Find Mesothelioma Specialists — Connect with experts nationwide
• Free Case Assessment — Get personalized guidance

Learn More About Treatment

• Treatment Options — Complete treatment guide
• Treatment Centers — Specialized facility information
• Survival Statistics — Prognosis and outcome data

---

1. [1] Journal of Thoracic Disease. (2018). Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma.
2. [2] National Comprehensive Cancer Network. (2026). NCCN Guidelines for Malignant Pleural Mesothelioma.
3. [3] Annals of Surgical Oncology. (2009). CRS-HIPEC for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience.
4. [4] Lung Cancer. (2018). Facility Volume and Postoperative Outcomes for Malignant Pleural Mesothelioma.
5. [5] Nature Medicine. (2025). Perioperative Nivolumab or Nivolumab Plus Ipilimumab in Resectable Pleural Mesothelioma.

Last updated: January 28, 2026

Related Articles

• Pleurectomy vs. Extrapleural Pneumonectomy: 5-Year Survival Rate Comparisons — Head-to-head survival data and selection criteria for EPP vs P/D